Latanoprost Vehicle

DRUG3 trials

Sponsors

Pfizer, Bausch & Lomb Incorporated

Conditions

Glaucoma, Open-AngleOcular HypertensionPrimary Open Angle GlaucomaPrimary Open-Angle Glaucoma

Phase 2

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

CompletedNCT00572455

PfizerOcular Hypertension, Primary Open-Angle Glaucoma

Start: 2007-12-11End: 2009-06-26Updated: 2021-04-30

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

CompletedNCT00595101

Bausch & Lomb IncorporatedOcular Hypertension, Primary Open Angle Glaucoma

Start: 2007-12-31End: 2008-06-30Updated: 2020-09-14

A Phase 2 Study Of The 24-Hour Intraocular Pressure Lowering And Systemic Exposure Of PF-04217329

CompletedNCT00934089

PfizerGlaucoma, Open-Angle, Ocular Hypertension

Start: 2010-01-31End: 2010-06-30Updated: 2021-05-03

Related Papers

A phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension.

2011-09-0138 citations